HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Hypometabolism exceeds atrophy in presymptomatic early-onset familial Alzheimer's disease.

AbstractUNLABELLED:
The aim of the present study is to compare brain atrophy with hypometabolism as preclinical markers of Alzheimer's disease (AD) by studying presymptomatic individuals from families with known early-onset autosomal dominant AD (FAD) carrying mutations in the Presenilin 1 gene.
METHODS:
Seven asymptomatic at-risk FAD individuals (age, 35-49 y; 4 women; education >/= 12 y) and 7 matched healthy control subjects received complete clinical, neuropsychologic, MRI, and (18)F-FDG PET examinations. Regions of interest (ROIs: whole brain [WB], hippocampus [Hip], entorhinal cortex [EC], posterior cingulate cortex [PCC], inferior parietal lobule [IPL], and superior temporal gyrus (STG]) were drawn on the MRI scans of all subjects and used to measure volumes on MRI and glucose metabolism (MRglc) from the MRI-coregistered, atrophy-corrected PET scans.
RESULTS:
Compared with controls and after correcting for head size, MRI volume reductions in FAD subjects were restricted to the IPL (18%, P < 0.02). After atrophy correction and adjusting for pons MRglc, PET MRglc reductions were found in all FAD subjects compared with controls in the WB (13%), bilaterally in the IPL (17%) and in the STG (12%), and in the left EC (21%), PCC (20%), and Hip (12%) (P values < 0.05). PET MRglc measurements were consistently less variable than MRI measures, yielding significantly larger effect sizes in separating FAD from controls.
CONCLUSION:
Presymptomatic FAD individuals show widespread MRglc reductions consistent with the typical AD PET pattern in the relative absence of structural brain atrophy. These data further suggest that PET MRglc measures may serve as biomarkers for the preclinical diagnosis of AD.
AuthorsLisa Mosconi, Sandro Sorbi, Mony J de Leon, Yi Li, Benedetta Nacmias, Paul S Myoung, Wai Tsui, Andrea Ginestroni, Valentina Bessi, Mozghan Fayyazz, Paolo Caffarra, Alberto Pupi
JournalJournal of nuclear medicine : official publication, Society of Nuclear Medicine (J Nucl Med) Vol. 47 Issue 11 Pg. 1778-86 (Nov 2006) ISSN: 0161-5505 [Print] United States
PMID17079810 (Publication Type: Journal Article, Research Support, N.I.H., Extramural)
Chemical References
  • Presenilin-1
Topics
  • Adult
  • Age of Onset
  • Alzheimer Disease (metabolism, pathology)
  • Atrophy
  • Brain (pathology)
  • Case-Control Studies
  • Disease Progression
  • Disease Susceptibility
  • Female
  • Humans
  • Magnetic Resonance Imaging (methods)
  • Male
  • Middle Aged
  • Positron-Emission Tomography
  • Presenilin-1 (metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: